FTC interim report finds three PBMs control nearly 80% of US prescriptions amid rebate scrutiny

By ··2 min read

The FTC's first interim staff report on pharmacy benefit managers found that the three largest PBMs processed nearly 80% of the 6.6 billion prescriptions dispensed in the US in 2023. The report documented vertical integration with insurers and specialty pharmacies and found PBM-affiliated pharmacies charging substantially higher prices than independents for the same drugs.

The Federal Trade Commission published its first interim staff report on the pharmacy benefit manager industry on July 9, 2024, drawing on compulsory process orders issued in 2022 to the six largest PBMs. The report found that Express Scripts, Caremark and OptumRx together processed nearly 80% of the approximately 6.6 billion prescriptions dispensed by US pharmacies in 2023, a level of concentration the agency described as posing risks to competition and drug affordability.

The report documented the degree to which the three PBMs had vertically integrated with health insurers, mail-order pharmacies and specialty pharmacies owned by the same parent. Express Scripts is owned by The Cigna Group, Caremark by CVS Health and OptumRx by UnitedHealth Group. The FTC found that this integration created conflicts of interest: each PBM could favour its affiliated pharmacy channel over independent competitors, and each had financial incentives to structure formularies in ways that directed volume to its own dispensing operations.

On specialty generics — a category that includes biosimilars and other complex injectables — the FTC found that PBM-affiliated pharmacies charged plan sponsors more than $7.3 billion above estimated acquisition costs between 2017 and 2022, a spread substantially higher than the margins earned by unaffiliated specialty pharmacies on the same products. The agency said these markups were obscured from plan sponsors by the integrated corporate structures.

The report also found that the PBMs' formulary strategies systematically preferred high list price, high rebate branded products over lower list price alternatives where the lower cost option would have better served patients whose cost-sharing is calculated from list price. The FTC cited insulin as the paradigmatic example: three manufacturers had introduced lower list price insulin products that the major PBMs largely excluded from their standard formularies in favour of higher list price products carrying larger rebates.

Commissioner Melissa Holyoak issued a partial dissent, questioning whether the report accurately characterised the evidence and arguing that rebates generally benefit plan sponsors. The PBMs criticised the report as biased and said it ignored the savings they generate for employers and government programmes.

The interim report directly preceded the FTC's September 2024 administrative complaint against the three PBMs over insulin rebating. Settlements with Express Scripts and Caremark followed in 2026. A second interim report published in January 2025 provided additional quantitative analysis of specialty generic markups.

Cite this report

The Precedent. "FTC interim report finds three PBMs control nearly 80% of US prescriptions amid rebate scrutiny." August 23, 2026. https://theprecedent.org/article/ftc-interim-report-finds-three-pbms-control-nearly-80-of-us-prescriptions-amid-r

Companies in this report